Markets
Nvidia CEO Jensen Huang
Jensen Huang, CEO of Nvidia (Johannes Neudecker/Getty Images)
Dr. Jensen and Mr. Huang

Nvidia is everything good and bad about the US stock market in 2026

AI-driven shortage beneficiary? Check. Buyer of memory chips? Check. A market leader facing mounting competition in AI boom? Check.

All the good and bad things about the US stock market in 2026 can be found in Nvidia. On steroids. 

The character of the AI trade has changed in 2026, becoming much more zero (even negative!) sum. Traders only seem eager to bid up stocks benefitting from acute AI-driven shortages (like memory), while punishing companies forced to accumulate these inputs at higher prices. And sellers are quick to make an example of the companies potentially disrupted by AI (see: software, or any industry Anthropic has referenced).

The conundrum with Nvidia is that it’s all of the above. It’s a massive buyer of memory chips, which are utilized in its racks, while the GPUs — the starring players in those racks — are persistently in short supply amid hot demand.

It’s been an AI winner, the epicenter of the AI boom, even. But the chip designer’s once-unquestioned dominance faces pointed queries given how Google’s Gemini 3 (trained on custom TPUs) drew widespread praise, and OpenAI was reportedly “unsatisfied” with how its chips perform in inference. Meta’s huge deal to buy AI infrastructure from Advanced Micro Devices, the #2 in GPUs, also has shares of Nvidia trading lower on Tuesday morning.

With its Q4 earnings due out Wednesday after the close, the chip designer’s fundamentals have been a microcosm of the S&P 500 and the wider market: earnings estimates up, multiples down.

With all these crosswinds, it’s no wonder that Nvidia has struggled to generate sustained momentum so far in 2026.

The Street’s View

Wall Street analysts, for their part, mostly believe that Nvidia will be able to convince investors that these apparent cross-currents are actually a wind at its back.

Analysts are looking for adjusted earnings per share of $1.53 on sales of a little more than $65.9 billion in Q4.

“Advanced wafer supply, CoWoS, and DRAM allocation have become points of constraint for server builds, but we believe NVDA has largely set its supply for Grace Blackwell and has better positioning vs. peers to work around bottlenecks further ensuring NVDA continues to hold its dominant share position through 2026,” writes Wedbush analyst Dan Ives.

However, some margin pressure may be in the offing as Nvidia deploys new generations of its GPUs. And, in the coming quarters, it may be difficult to distinguish whether any headwinds to profitability are functions of the Vera Rubin ramp, higher input prices, or some mix of the two.

JPMorgan analyst Harlan Sur expects Jensen Huang & Co. to indicate that gross margins will be in the mid-70s in the near term, while noting that, in light of the above factors, confidence surrounding this “remains an open question.”

He also thinks the company will aim to reassure investors that its inference capabilities are robust, countering concerns that custom chips will pose an escalating threat to its dominant market position. To this end, near the end of Q4, Nvidia reached a licensing deal (effectively an acquisition) of AI inference specialist Groq. Sur writes:

“A broader, more overarching theme that we think has weighed on the stock is the perception of share loss relative to AI ASICs/XPUs, as the aggregate mix of AI workloads rapidly shifts more towards inference (where specialized/custom silicon can be especially beneficial) and away from training (where NVDA is the undisputed leader).”

Continuing, the JPMorgan analyst notes:

“On this front, we expect management to emphasize significant gen-on-gen gains in inference performance (as demonstrated by recent third-party benchmarking), and at least lift the veil slightly on products currently in the pipeline that leverage Groq IP for specialized, low-latency inference at scale.”

Why so cheap?

The colossal, far bigger than expected capex budgets put forward by hyperscalers are, in a very real sense, Nvidia’s earnings guidance: chips are the biggest line item for data centers.

Why hasn’t Nvidia benefited meaningfully from these investment plans?

The reasons, in my eyes, are twofold:

First, there are more intense AI shortages that commanded investor attention. The obvious example is Sandisk, the best-performing member of the S&P 500 with a 181% return year-to-date (and indeed the best-performing of last year). The flash drive seller’s 12-month forward price to earnings ratio has gone down during this rally — that is, the shares have become cheaper because of just how much forward earnings estimates have risen.

Second, 2026 investment plans from Nvidia’s biggest customers are great news for the chip designer’s 2026 earnings outlook. But the performance of those tech giants in the stock market is a signal.

They say money goes where it’s treated best. If investors are taking money out of hyperscalers because those companies are pouring it into AI capex with an uncertain return, well, at some point, those executives are also going to do something else with their money in a bid to engineer a better outcome in the stock market.

More Markets

See all Markets
Constellation Energy Q4 Earnings report

Top AI-energy trade Constellation Energy beats earnings expectations

The company declined to give full-year 2026 guidance until a call slated for the end of March.

markets

Cipher Mining slumps after Q4 results disappoint

Cipher Mining is sinking in premarket trading today after missing revenue and earnings estimates for the last quarter of 2025, with the stock down 4.5% at 7:30 a.m. ET.

For Q4, the company reported:

  • Revenue: $60 million (estimate: $84.4 million)

  • Adjusted earnings per share: -$0.14 (estimate: -$0.06)

After the close on Monday, crypto miner Canaan announced that it had purchased Cipher Mining’s stake in a mining joint venture for $39.75 million, deepening Cipher’s pivot away from bitcoin mining toward data centers. Indeed, CIFR acknowledged in the Q4 and year-end report that its “identity has evolved to focus on enabling next-generation compute at industrial scale.”

The Canaan acquisition news came on the heels of former bitcoin miner Bitdeer announcing that it had sold all of its bitcoin holdings to fund its pivot to AI.

markets

AMD soars after striking AI chip deal with Meta valued at over $100 billion

Advanced Micro Devices is spiking in premarket trading on Tuesday after the company booked another major customer for its GPUs.

The chip designer struck a deal with Meta to deploy 6 gigawatts worth of AI infrastructure (that is, multiple generations of AMD AI chips). Per The Wall Street Journal, AMD has said that each gigawatt is equivalent to “several tens of billions of dollars” of sales, making the value of this pact in excess of $100 billion.

In exchange, Meta will receive warrants to buy as many as 160 million shares — roughly 10% of AMD’s current total shares outstanding — for a penny each as certain milestones are hit pertaining to the amount of gigawatts shipped, AMD’s share price, and “Meta achieving key technical and commercial milestones.” For all the tranches to vest, AMD stock would need to trade at $600.

The GPUs-for-warrants framework is similar to the deal that AMD brokered with OpenAI last year.

Mark Zuckerberg has a voracious appetite for AI compute. Just last week, Meta unveiled a “multi-year, multi-generational strategic partnership” with Nvidia that “will enable the large-scale deployment of NVIDIA CPUs and millions of NVIDIA Blackwell and Rubin GPUs, as well as the integration of NVIDIA Spectrum-X Ethernet switches for Meta’s Facebook Open Switching System platform.”

Nvidia, the leader in AI GPUs, slumped as news of this pact hit the wires.

markets

IBM had its worst trading day since the dot-com bubble burst

It’s Blue Monday... or it certainly was for IBM yesterday, as the stock suffered its biggest one-day drop since 2000, when the technology company’s shares tanked amid the wider bursting of the dot-com bubble.

Big Blue wound up in the big red, shedding more than 13% by yesterday’s close, fueled by an Anthropic blog post detailing Claude Code’s ability to automate modernization of Common Business-Oriented Language (COBOL) code.

COBOL’s ubiquity and antiquity, the language will celebrate its 67th birthday in September, makes it a pretty big deal — and a pretty big pain — not least for IBM, which is behind most of the mainframe computers that run the language, per Bloomberg.

IBM hit back with its own blog post yesterday outlining that the value its core mainframe computer business delivers isn’t dependent on a single language like COBOL or Java, but on the platform itself. The company also highlighted watsonx, its own AI tool suite which has COBOL modernization capabilities.

COBOL’s ubiquity and antiquity, the language will celebrate its 67th birthday in September, makes it a pretty big deal — and a pretty big pain — not least for IBM, which is behind most of the mainframe computers that run the language, per Bloomberg.

IBM hit back with its own blog post yesterday outlining that the value its core mainframe computer business delivers isn’t dependent on a single language like COBOL or Java, but on the platform itself. The company also highlighted watsonx, its own AI tool suite which has COBOL modernization capabilities.

markets

Hims discloses SEC probe as its legal woes mount

Hims & Hers said that it is under investigation by the Securities and Exchange Commission, adding another legal challenge for the telehealth company.

The SEC requested that it preserve records related to its compounded GLP-1 treatments, Hims disclosed in a regulatory filing on Monday. The news came after the company reported earnings results and gave soft full-year guidance.

Shares extended losses to down more than 8% in postmarket trading after the 10-K, which detailed this probe, was released.

Hims is already facing a patent infringement lawsuit from Novo Nordisk and a potential probe from the Department of Justice. Both arose after Hims released (and then discontinued) a copy of Novos Wegovy pill.

Hims is already facing a patent infringement lawsuit from Novo Nordisk and a potential probe from the Department of Justice. Both arose after Hims released (and then discontinued) a copy of Novos Wegovy pill.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.